Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Musculoskeletal Changes After Physiotherapeutic Intervention in Podiatric Subjects (BIONEDIAN)

3. februar 2020 oppdatert av: Mgr. Eliška Vrátná

Musculoskeletal Changes Induced by Physiotherapeutic Intervention, and Their Impact on the Induction of Diabetic Foot Syndrome and Psychosocial Status in Type 2 Diabetes Mellitus

The recurrence of diabetic foot ulcers (DFU) is a key problem in podiatric care. It is very often given by biomechanical abnormalities frequently present in those patients. The aim of our randomized controlled study is to find possible changes as of plantar pressures as of biomechanics of the ankle and small joints in patients with type 2 diabetes mellitus with different degrees of neuropathy. During this project, investigators will examine the possible impact of 12-week lasting intervention program on the distribution of plantar pressures, joint mobility and muscle strength of lower limbs. The incidence of ulcerations / reulcerations and changes of psychosocial characteristics will be evaluated during the study period.

Approximately 60 patients with Type 2 diabetes mellitus will be included into the study. These patients will be randomized into 3 study groups - patients with type 2 DM with mild form of peripheral sensory neuropathy (20 subjects), patient with severe peripheral neuropathy (20 subjects) and those with diabetic foot syndrome, without active lesion (20 subjects). All patients will undergo 12 week lasting active intervention program consisting of recommendations by a physiotherapist focusing on the improvement of physical fitness, muscle strength and foot joint improvement. Control group will be consisted of 20 patients with healed diabetic foot.

The outcomes of this project will try to objectively verify in the randomized controlled trial the impact of exercise on lower limb biomechanics, mobility, self-sufficiency, quality of life in patients with type 2 diabetes mellitus at risk or already developed diabetic foot syndrome.

Studieoversikt

Status

Ukjent

Studietype

Intervensjonell

Registrering (Forventet)

80

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Prague, Tsjekkia, 14200
        • Rekruttering
        • Institute for Clinical and Experimental Medicine
        • Ta kontakt med:
        • Ta kontakt med:
          • Vladimíra Fejfarová, MD, PhD
          • Telefonnummer: +420603877381
          • E-post: vlfe@medicon.cz
        • Underetterforsker:
          • Jitka Hazdrová, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Type 2 diabetes mellitus
  • sensoric neuropathy (mild - based on VPV 15-30 V or EMG results, severe - based on VPT above 50 V or EMG results)
  • diabetic foot with healed diabetic foot ulcers, inactive Charcot foot

Exclusion Criteria:

  • impossibility to exercise
  • amaurosis
  • non-compliance
  • critical limb ischemia
  • active ulcer, surgical wound
  • active Charcot foot
  • active carcinoma
  • recent stroke (last 8 weeks)
  • recent myocardial infarction (last 8 weeks)
  • recent PTA, PCI, bypass (last 8 weeks)
  • myopathy
  • rheumatoid arthritis
  • cox-, gonartrosis of 3rd -4th grade.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: DF patient active
Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
12 week lasting exercise intervention
Aktiv komparator: DF patient control
Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
12 week lasting exercise intervention
Eksperimentell: Diabetic patient with mild neuropathy
Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
12 week lasting exercise intervention
Eksperimentell: Diabetic patient with severe neuropathy
Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
12 week lasting exercise intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Biomechanics- plantar pressures
Tidsramme: changes after 12 weeks, 24 weeks
plantar pressures will be evaluated by pedobarograph (in Newtons)
changes after 12 weeks, 24 weeks
Biomechanics- biomechanics of the ankle
Tidsramme: changes after 12 weeks, 24 weeks
biomechanics of the ankle will be assessed by goniometry in angles
changes after 12 weeks, 24 weeks
Biomechanics- changes of foot joint angles
Tidsramme: changes after 12 weeks, 24 weeks
changes of foot joint agles will be evaluated by measurement of X-Rays bones angles - calcaneal pitch, talar-1st metatarsal angle and lateral Talocalcaneal angle
changes after 12 weeks, 24 weeks
Fitness - physical activity
Tidsramme: changes after 12 weeks, 24 weeks
The amount of physical activity will be assessed by IPAQ questioners
changes after 12 weeks, 24 weeks
Fitness - muscle strength
Tidsramme: changes after 12 weeks, 24 weeks
Muscle strength will be measured by dynamometry in Newtons
changes after 12 weeks, 24 weeks
Fitness - senior fitness
Tidsramme: changes after 12 weeks, 24 weeks
fitness will be assessed by seniorfittest containing 2 minutes step test (steps/2 min) and test of sitting (sits/30 seconds)
changes after 12 weeks, 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ulceration/reulceration
Tidsramme: changes after 12 weeks, 24 weeks
detection of the incidence of ulceration/reulceration
changes after 12 weeks, 24 weeks
Psychosocial changes - quality of life
Tidsramme: changes after 12 weeks, 24 weeks
Quality of life will be evaluated by WHO-QoL Bref test (4 domains - high values mean bettr findings
changes after 12 weeks, 24 weeks
Psychosocial changes - depression
Tidsramme: changes after 12 weeks, 24 weeks
Depression status will be asessed by Geriatric Depression Scale (GDS) scale - minimum 0, maximum 30 points (higher then 9 points- mild form of depression, higher then 20 - severe depression
changes after 12 weeks, 24 weeks
Psychosocial changes - stress readaptation
Tidsramme: changes after 12 weeks, 24 weeks
Adaptation to stress will be detected by Stress Readaption Scale (0-400 points) - points higher then 150 - higher risk of worse stress readaptation and therefore higher risk of somatisation
changes after 12 weeks, 24 weeks
Metabolism - glucose control
Tidsramme: changes after 12 weeks, 24 weeks
Investigators will be loked for metabolic changes in diabetes control (HbA1c in mmol/mol, glycemia in mmol/l)
changes after 12 weeks, 24 weeks
Metabolism - lipid profile
Tidsramme: changes after 12 weeks, 24 weeks
The authors will control lipid profiles (Total-, HDL-, LDL-cholesterol in umol/l)
changes after 12 weeks, 24 weeks
Metabolism - myokines
Tidsramme: changes after 12 weeks, 24 weeks
Patients will be checked for changes in selected cytokines nad myokines (IL-4,6,7,8,15 in pg/ml, myostatin in pg/ml, irisin in ng/ml, FGF-21 in pg/ml)
changes after 12 weeks, 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2019

Primær fullføring (Forventet)

30. mars 2020

Studiet fullført (Forventet)

1. januar 2021

Datoer for studieregistrering

Først innsendt

15. desember 2019

Først innsendt som oppfylte QC-kriteriene

3. februar 2020

Først lagt ut (Faktiske)

6. februar 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. februar 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. februar 2020

Sist bekreftet

1. februar 2020

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ubestemt

IPD-planbeskrivelse

Possible to look at the data in documentation site

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere